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Prevalence and Profile of Nonalcoholic
Fatty Liver Disease in Lean Adults:
Systematic Review and Meta-Analysis
Steven Young,1 Raseen Tariq,2 John Provenza,3 Sanjaya K. Satapathy
Ashwani K. Singal

8,9

,4 Kamal Faisal,5 Abhijit Choudhry,6 Scott L. Friedman,7 and

Data on prevalence and profile of nonalcoholic fatty liver disease (NAFLD) among individuals who are lean (normal
body mass index) is unclear. Published data from studies comparing lean with obese NAFLD or with healthy subjects
on prevalence, comorbidities, liver chemistry and histology, and metabolic/inflammatory markers were analyzed. Data
were reported as odds ratio and 95% confidence interval for categorical variables and difference of means for continuous variables. Analysis of 53 studies on 65,029 subjects with NAFLD (38,084 lean) and 249,544 healthy subjects
showed a prevalence of lean NAFLD at 11.2% in the general population. Among individuals with NAFLD, the prevalence of lean NAFLD was 25.3%. Lean NAFLD versus healthy subjects had higher odds for abnormalities on metabolic profile, including metabolic syndrome and its components, renal and liver function, and patatin-like phospholipase
domain-containing protein 3 (PNPLA3) G allele; and inflammatory profile, including uric acid and C-reactive protein.
The abnormalities were less severe among lean versus obese NAFLD on metabolic syndrome with its components,
renal and liver chemistry, liver stiffness measurement, PNPLA3 and transmembrane 6 superfamily member 2 polymorphisms, and uric acid levels as markers of inflammation. Lean NAFLD had less severe histologic findings, including
hepatocyte ballooning, lobular inflammation, NAFLD activity score, and fibrosis stage. Limited data also showed worse
outcomes between obese versus lean NAFLD. Conclusion: Lean NAFLD is a distinct entity with metabolic, biochemical, and inflammatory abnormalities compared to healthy subjects and a more favorable profile, including liver histology of steatohepatitis and fibrosis stage, compared to obese NAFLD. We suggest that prospective multicenter studies
examine long-term hepatic and extrahepatic outcomes in individuals with lean NAFLD. (Hepatology Communications
2020;4:953-972).

N

onalcoholic fatty liver disease (NAFLD)
is one of the most common liver diseases
in the world, with a global prevalence of
approximately 25% and a prevalence of 24% in North
America.(1,2) The incidence is increasing, especially

in the Western world, due to the rising prevalence of
obesity in the general population.(3) Approximately
15% to 20% of patients with NAFLD progress to the
more advanced stage of nonalcoholic steatohepatitis
(NASH), with a risk to progress to advanced liver
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interval; CRP, C-reactive protein; HDL, high-density lipoprotein; HOMA-IR, homeostatic model for insulin resistance; NAFLD, nonalcoholic
fatty liver disease; NAS, nonalcoholic fatty liver disease activity score; NASH, nonalcoholic steatohepatitis; OR, odds ratio; PNPLA3, patatin-like
phospholipase domain-containing protein 3; TM6SF2, transmembrane 6 superfamily member 2.
Received November 20, 2019; accepted March 18, 2020.
Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep4.1519/suppinfo.
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals Inc., on behalf of American Association forthe Study of Liver
Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use
and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modif ications or adaptations are
made.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep4.1519
Potential conflict of interest: Nothing to report.

953

YOUNG ET AL.

disease, including cirrhosis and hepatocellular carcinoma.(1) Currently, NASH is the second most common indication for liver transplantation, surpassing
hepatitis C virus infection and lagging behind alcoholassociated liver disease.(4,5)
Risk factors for NAFLD include insulin resistance and metabolic syndrome (≥3 of obesity, diabetes
mellitus, hypertension, low high-density lipoprotein
[HDL], and high triglyceride levels).(1) Of these, the
most common and frequent risk factor is obesity.(1)
However, NAFLD can occur among individuals who
are not obese and have a normal body mass index
(BMI). These individuals are labeled as “lean NAFLD”
or “nonobese NAFLD.”(1) Data on the prevalence of
lean NAFLD among healthy adults in the general
population vary from 7.8% to 74% across studies.(6-9)
This is mainly due to the variation in the BMI cutoff
used to define individuals who are lean: 25 in studies
from the West,(10) 23 in studies from Asia,(6,11) and 30
in some studies given that obesity is defined as BMI
>29.9.(12) Further, data remain unclear on the metabolic profile of lean NAFLD and whether this is an
early manifestation of obese NAFLD or a separate
entity.(9,13,14) Data are also scanty and controversial
on the histology spectrum and outcomes among lean
NAFLD compared to obese NAFLD. We performed
this systematic review and meta-analysis of all studies to determine the prevalence of lean NAFLD. We
further examined studies comparing lean and obese
NAFLD on comorbidities and risk factors, metabolic and inflammatory markers, and liver histology
findings.
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Materials and Methods

LITERATURE SEARCH STRATEGY

We conducted a comprehensive search of the
medical literature using the PubMed, Embase, and
Cochrane databases. We followed the Preferred
Reporting Items for Systematic Reviews and MetaAnalysis (PRISMA) guidelines to identify full-length
articles in English reporting on lean NAFLD. All
databases were searched from their inception through
August 2019. Studies on lean NAFLD were identified using the following initial medical subject heading terms: “lean” “non-obese” “non-alcoholic fatty
liver disease,” “non-alcoholic fatty liver,” “nonalcoholic
fatty liver,” “nafld,” “nonalcoholic-steatohepatitis,” and
“non-alcoholic-steatohepatitis.”

SELECTION OF STUDIES FOR
ANALYSIS
From the searched literature, studies of adults were
included in this pooled analysis that reported: a) the
prevalence of lean NAFLD and/or b) the disease profile of lean NAFLD comparing with obese NAFLD
or with healthy individuals who were lean. Prospective
as well as retrospective studies were included. Studies
were excluded if they reported data on the pediatric
population; were mechanistic or animal studies; were
reported as abstracts, case reports, editorials, reviews,
meta-analyses, or clinical trials; and were published
in a non-English language. In the case of multiple
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publications from the same cohort, data from the most
recent and/or most appropriate report were included.
Three authors (S.Y., A.K.S., and K.F.) independently
reviewed the titles and abstracts of the studies identified in the primary search and excluded studies that
did not address the research according to the inclusion
and exclusion criteria. The full text of the remaining
articles was reviewed for study selection. Any disagreement was resolved with a review of the article
and discussion among the co-authors.

ASSESSMENT OF STUDY QUALITY
Each study was reviewed by two independent
reviewers (S.Y. and J.P.) for quality using eight parameters on the Newcastle-Ottawa scale for the casecontrol or cohort studies. This scale measures each
study on three domains: selection, comparability, and
exposure (Supporting Table S1). In addition, studies
were assessed on sample size (population-based study
or sample size ≥500 for nonpopulation studies were
adjudicated 1 point) and study design (prospective
studies were adjudicated 1 point). Of the maximum
score of 10, studies with ≥6 points were rated as good
quality and the remaining as poor quality.

DATA EXTRACTION
Published data from all studies selected for the
analysis were extracted independently by three authors
(S.Y., K.F., and A.K.S.) based on seven criteria. Any
disagreement between the investigators was resolved
with consensus after review of the study data in question. The criteria were as follows:
1. Study characteristics: geographic location, study
design, sample size, study population.
2. Demographics: age, sex, race, and BMI.
3. NAFLD prevalence: overall, lean NAFLD, and
obese NAFLD.
4. Comorbidities and risk factors: metabolic syndrome, increased waist circumference, central obesity, hypertension, dyslipidemia, diabetes mellitus,
impaired fasting glucose, low HDL, elevated triglycerides, insulin resistance, coronary artery disease, carotid plaque, smoking, hyperuricemia, and
genetic polymorphisms for patatin-like phospholipase domain-containing protein 3 (PNPLA3)
and transmembrane 6 superfamily member 2
(TM6SF2) genes.
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5. Metabolic and inflammatory markers: waist circumference; waist to hip ratio; blood pressure;
blood lipid panel, including total cholesterol,
HDL, low-density lipoprotein (LDL), and triglycerides; fasting glucose, 2-hour postprandial
glucose, hemoglobin A1c, fasting insulin level,
and homeostatic model assessment for insulin
resistance (HOMA-IR); serum ferritin; serum
C-reactive protein (CRP); serum uric acid; and

carotid intima-media thickness.
6. Hematologic and biochemical assessment: hemoglobin, hematocrit, platelet count, blood urea nitrogen, serum creatinine, serum bilirubin, alkaline
phosphatase (ALP), aspartate aminotransferase
(AST), alanine aminotransferase (ALT), gammaglutamyltransferase, and serum albumin.
7. Liver histology: steatosis, lobular inflammation,
ballooning, portal inflammation, fibrosis stage,
NAFLD activity score (NAS), and NASH.
Patients with lean NAFLD were compared to
healthy controls and patients with obese NAFLD.
For comparison of obese versus lean NAFLD, subgroup analysis was also performed among nine
studies, including individuals who were overweight.
Data on continuous variables were reported as
mean, with unit of variation as SD. If the studies
reported continuous variables with median values,
they were converted into mean using the standard
approach. Similarly, if the unit of variation was reported as SEM, this was converted to SD to ensure
uniformity of the data across studies. If the laboratory values were reported as molar concentration,
conversion was made using the standard approach
for respective values to mass concentration to ensure a homogeneous unit of measurement across
studies.

DEFINITIONS
We used the following definitions:
1. NAFLD: hepatic steatosis in the absence of other
causes of liver disease and alcohol use <30 g/day in
men and <20 g/day in women.(1)
2. Lean: BMI <25 in Western studies and <23 in
most studies from Asia.
3. Metabolic syndrome: presenting with ≥3 of the
following: abdominal or central obesity (waist circumference >40 inches in men and >35 inches in
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women), triglyceride level ≥150 mg/dL, HDL level
<40 mg/dL in men and <50 mg/dL in women,
blood pressure ≥130/85 mm Hg, and fasting glucose ≥110 mg/dL.(15)
4. HOMA-IR: fasting insulin level (μU/L) × blood
glucose level (mg/dL).(1)
5. Steatosis grade: on liver histology with a percentage of hepatocytes showing fat as grade
1 (5%-33%), grade 2 (34%-66%), and grade 3
(≥66%).(16)
6. Lobular inflammation grade: graded by number of inflammatory foci per 200× field as grade
1 (<2 foci), grade 2 (2-4 foci), and grade 3 (>4
foci).(16)
7. Hepatocyte ballooning grade: graded by number of ballooned hepatocytes as grade 1 (few
ballooned cells) and grade 2 (many ballooned
cells).(16)
8. NAS: sum of the scores for steatosis, lobular inflammation, and ballooning.(16)
9. NASH: defined on liver histology with NAS
≥5.(16)
10. Fibrosis stage: graded as stage 1 with perisinusoidal or portal fibrosis, stage 2 with periportal fibrosis, stage 3 as bridging fibrosis, and stage 4 with
cirrhosis.(16)

DATA ANALYSES
Comprehensive statistical analysis software was used
to pool the published data on the analyses. Random
effects model was used to analyze pooled data, and
the pooled effect size was represented as forest plots.
Effect size on categorical variables data is reported as
proportions or odds ratio (OR) with 95% confidence
interval (CI). OR not crossing 1 is considered significant. Effect size on continuous variables is reported
as differences of means with 95% CI and considered
significant if the 95% CI does not cross 0. P < 0.05
was considered significant for all analyses. Interstudy
heterogeneity was examined using I2 statistics and
defined as I2 > 50% or P < 0.05.(17) For heterogeneous
data, subgroup or sensitivity analyses were performed
to examine reasons for heterogeneity. Publication bias
was assessed by visual inspection of funnel plots and
with Egger’s regression test, with P < 0.05 considered
significant for the presence of publication bias.(18)

956

Hepatology Communications, July 2020

Results

BASELINE CHARACTERISTICS

Of the 424 studies identified in the initial literature search, 53 were included in the analysis (Supporting Fig. S1) on 65,029 subjects with
NAFLD (38,084 lean) and 249,544 subjects who
were healthy. Of these, 42 studies were reported
from Asia, six from Europe, five from the Middle
East, and two from North America (Table 1). There
were 46 studies of good quality, and the remaining
seven were adjudicated as poor quality with a study
quality score of <6 (Supporting Table S1). Mean age
was similar when comparing subjects with obese
versus lean NAFLD, with a mean difference of 0.26
(95% CI, −0.35 to 0.86; P = 0.40). However, subjects
with lean NAFLD compared to subjects who were
healthy and lean were older, with a mean difference
of 0.70 (95% CI, 0.44-0.96; P < 0.001). Data were
heterogeneous with I2 = 99, P < 0.001, but without
publication bias on either analysis. There were no
differences in the proportion of smokers comparing
subjects with obese NAFLD versus lean NAFLD
from seven studies and lean NAFLD versus subjects who were healthy from 10 studies (OR, 0.91;
95% CI, 0.51-1.61; P = 0.74 and OR, 1.23; 95% CI,
0.93-1.63; P = 0.14, respectively).

PREVALENCE OF LEAN NAFLD
Pooled data from 30 studies showed a prevalence
of lean NAFLD in the general population of 11.2%
(95% CI, 9.6-13.0) (Fig. 1A) and 9.2% (95% CI,
7.4-11.3) from 15 studies and a sample size ≥1,000
subjects (Fig. 1B). Based on geographic location,
the prevalence of lean NAFLD was 12% (95% CI,
10.2-14.2) in Asia from 23 studies, 10.2% (95% CI,
6.3-16.0) in the Middle East from four studies, and
9.2% (95% CI, 8.4-10.2) on the Western continent
from three studies (Supporting Fig. S2). Among
five studies of adults who were lean, the pooled
prevalence of NAFLD was 12.6% (95% CI, 9.017.4). Among 24 studies that included adults who
were not lean, the pooled prevalence of NAFLD
was 26.0% (95% CI, 21.6-30.9), 10.9% (95% CI,
9.1-12.8) in subjects who were overweight, and
46.0% (95% CI, 36.3-56.1) in subjects with obesity.
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FIG. 1. Prevalence of lean NAFLD. (A) Pooled prevalence of lean NAFLD, (B) population prevalence of lean NAFLD, (C) prevalence of lean NAFLD among all NAFLD, and
(D) population prevalence of lean NAFLD among all NAFLD. The graph represents effect size from each study and black square represents the pooled effect size.
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Among subjects with NAFLD, the proportion
of lean NAFLD analyzed from 15 studies was
25.3% (95% CI, 17.0-35.7) (Fig. 1C) and 22.4%
(95% CI, 14.1-33.6) from 12 studies with a sample size ≥1,000 subjects (Fig. 1D). All analyses on
pooled prevalence showed heterogeneous data with
I2 ≥ 75%. However, there was no publication bias
(P > 0.05).

METABOLIC AND INFLAMMATORY
MARKERS

Obese Versus Lean NAFLD

Of 34 studies included in the analysis, 28 on 21,860
subjects with obese NAFLD and 7,349 subjects with
lean NAFLD reported data on some or all of the
markers of interest.
For the metabolic markers, subjects with obese
NAFLD compared to lean NAFLD had higher mean
systolic and diastolic blood pressure, hemoglobin A1C,
and HOMA-IR (Supporting Fig. S3A-D). Mean
serum level was lower for HDL and higher for triglycerides among obese NAFLD versus lean NAFLD
(Supporting Fig. S3E,F). However, the data were
similar on pooled mean difference for fasting insulin
from eight studies, 1.22 (95% CI, −0.10 to 2.55; P =
0.48); fasting glucose from 26 studies, −0.13 (95% CI,
−0.78 to 0.51; P = 0.68); 2-hour postprandial glucose
from four studies, −0.03 (95% CI, −0.19 to 0.40; P =
0.69); total cholesterol from 25 studies, 0.48 (95% CI,
−0.04 to 0.99; P = 0.07); and LDL from 20 studies,
0.69 (95% CI, −0.03 to 1.41; P = 0.062). Data were
heterogeneous on all the analyses except for hemoglobin A1C, and there was no publication bias on any
of the analyses (Egger’s regression test) (Supporting
Table S2).
For biochemical and hematologic markers, subjects with obese NAFLD compared to those with
lean NAFLD had higher mean serum ALT, albumin, and creatinine levels (Fig. 2A,B,D). Other biochemical data were similar for AST from 24 studies,
0.41 (95% CI, −0.009 to 0.81; P = 0.045); ALP
from seven studies, −0.06 (95% CI, −0.15 to 0.03;
P = 0.17); total bilirubin from four studies, −0.04
(95% CI, −0.14 to 0.07; P = 0.53); and blood urea
nitrogen from four studies, −0.06 (95% CI, −0.14 to
0.02; P = 0.16). On hematologic evaluation, obese
NAFLD compared to lean NAFLD had higher
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mean hemoglobin levels (Fig. 2C) but similar platelet counts from four studies, 0.76 (95% CI, −1.3 to
2.80; P = 0.47). Pooled data on all the analyses were
heterogeneous except for hemoglobin and serum
bilirubin. There was no publication bias for any of
the analyses (Egger’s regression test) (Supporting
Table S2).
For the liver stiffness measurement, pooled values
from two studies comparing 407 subjects with obese
NAFLD and 207 subjects with lean NAFLD showed
higher values in obese NAFLD (Fig. 2F). Data were
homogeneous (I2 = 0; P = 0.92), and publication bias
could not be assessed with only two studies in the
analysis.
For inflammatory markers, subjects with obese
NAFLD compared to those with lean NAFLD had
higher mean uric acid levels (Fig. 2E). Analyses for
other inflammatory markers were similar on mean
serum ferritin from four studies, 0.15 (95% CI,
−0.04 to 0.35; P = 0.12); CRP from five studies,
0.13 (95% CI, −0.04 to 0.31; P = 0.13); and carotid
intima-media thickness from two studies, 0.01 (95%
CI, −0.93 to 0.95; P = 0.98). Data were heterogeneous for all the analyses but without any publication bias (Egger’s regression test) (Supporting
Table S2).
In a subgroup analysis after excluding nine studies that included patients who were overweight in
the lean group, the results of all the analyses were
similar (Supporting Table S3). We also performed
subgroup analyses from seven studies comparing individuals with obesity without NAFLD and those who
were lean without NAFLD to discern the effect of
NAFLD itself (Supporting Table S4). Groups with
obesity versus lean groups had worse metabolic and
inflammatory profiles.

Lean NAFLD versus healthy lean

Data for markers comparing lean NAFLD versus
subjects who were healthy were extracted from 33
studies on 36,029 subjects with lean NAFLD and
243,815 subjects who were healthy.
For metabolic markers, subjects with lean NAFLD
compared to healthy subjects who were lean without NAFLD had higher mean BMI, diastolic blood
pressure, hemoglobin A1C, and insulin resistance
(Supporting Fig. S4A-D). The lipid profile showed
lower mean levels for HDL and higher triglyceride
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FIG. 2. Pooled data on liver biochemical markers of subjects with obese NAFLD versus those with lean NAFLD. (A) ALT, (B) albumin,
(C) hemoglobin, (D) creatinine, (E) uric acid, and (F) liver stiffness measurement. The graph represents effect size from each study and
black square represents the pooled effect size.
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levels among subjects with lean NAFLD compared
to healthy subjects without NAFLD (Supporting
Fig. S4E,F). Lean NAFLD also had higher mean
waist circumference from 22 studies, 0.81 (95% CI,
0.71-0.91); waist to hip ratio from five studies, 0.67
(95% CI, 0.43-0.92); systolic blood pressure from
25 studies, 0.36 (95% CI, 0.27-0.45); fasting glucose from 31 studies, 1.51 (95% CI, 1.21-1.80); and
2-hour postprandial glucose from four studies, 0.45
(95% CI, 0.28-0.62; P < 0.001 for all analyses). Data
were heterogeneous on all the analyses except for
2-hour postprandial glucose (I2 = 0; P = 0.54). There
was publication bias on analysis for waist circumference (Egger’s P = 0.03) but not for any other analysis
(Supporting Table S5).
For biochemical and hematologic markers, subjects with lean NAFLD compared to healthy subjects without NAFLD had higher mean serum
ALT, ALP, and total bilirubin levels (Fig. 3A-C).
Subjects with lean NAFLD also had higher mean
serum AST from 27 studies, 0.91 (95% CI, 0.631.19; P < 0.001); and similar serum albumin levels
from three studies, 0.005 (95% CI, −0.48 to 0.49;
P = 0.98). Subjects with lean NAFLD had higher
mean serum creatinine compared to healthy subjects
without NAFLD (Fig. 3D). On hematologic assessment, there were no differences comparing subjects
with lean NAFLD and healthy subjects on blood
hemoglobin from four studies, 0.76 (95% CI, −0.06
to 1.57; P = 0.09); and platelet count from six studies, −0.70 (95% CI, −2.06 to 0.66; P = 0.31). Data
were heterogeneous for all the analyses except total
bilirubin (I2 = 33; P = 0.2). There was no publication bias on any of the analyses except for serum
creatinine analysis (Egger’s P = 0.03) (Supporting
Table S5).
For inflammatory markers, subjects with lean
NAFLD compared to healthy subjects had higher
mean serum CRP and uric acid levels (Fig. 3E,F).
However, there were no differences on mean serum
apolipoprotein A from two studies, −2.29 (95% CI,
−7.18 to 2.61; P = 0.36). Data were heterogeneous
with publication bias by Egger’s regression test
for CRP (Egger’s P = 0.04) but not for analyses of
uric acid (Egger’s P = 0.36) (Supporting Table S5).
Publication bias could not be assessed for apolipoprotein A comparison because there were only two studies in this analysis.
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RISK FACTORS AND
COMORBIDITIES

Obese NAFLD Versus Lean NAFLD

Of 34 studies included in the analysis, 17 on 9,321
subjects with obese NAFLD and 4,832 subjects
with lean NAFLD reported data on risk factors or
comorbidities.
Odds of central obesity, hypertension, type 2 diabetes mellitus, impaired fasting glucose, low HDL, and
metabolic syndrome were significantly higher among
subjects with obese NAFLD compared to subjects with
lean NAFLD (Fig. 4A-F). Subjects with obese NAFLD
compared to those with lean NAFLD also had approximately a 4-fold risk for increased waist circumference
(OR, 3.76; 95% CI, 2.51-5.63; P < 0.001). However,
there were no differences on elevated triglycerides from
four studies (OR, 1.28; 95% CI, 0.82-2.0; P = 0.28),
dyslipidemia from eight studies (OR, 1.42; 95% CI,
0.83-2.42; P = 0.20), and smoking status from eight
studies (OR, 0.96; 95% CI, 0.61-1.54; P = 0.88).
Odds of coronary artery disease assessed in one
study did not find any difference comparing subjects
with obese NAFLD versus those with lean NAFLD
(OR, 1.84; 95% CI, 0.10-34.02; P = 0.68). However,
carotid plaques assessed in another study showed
higher odds among subjects with obese versus lean
NAFLD (OR, 2.24; 95% CI, 1.41-3.56; P < 0.001).
None of these studies examined clinical outcomes
or development of cardiac events. There was no difference in prevalence between subjects with obese
NAFLD and those with lean NAFLD with respect to
genetic polymorphisms for PNPLA3 (reported in six
studies) and TM6SF2 genes (reported in three studies) (OR, 0.75; 95% CI, 0.53-1.07; P = 0.11 and OR,
0.49; 95% CI, 0.18-1.3; P = 0.15, respectively). Data
were homogeneous for analyses on central obesity,
low HDL, and impaired fasting glucose. Remaining
analyses showed heterogeneous data with I2 > 50 or
P < 0.05. There was no publication bias for any of
the analyses (Supporting Table S6) except for dyslipidemia analysis.

Lean NAFLD Versus Healthy Lean

A total of 20 studies on 5,515 subjects with lean
NAFLD and 54,652 healthy controls reported data
on some or all of the markers of interest.
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FIG. 3. Pooled data on liver chemistry and biochemical markers of subjects with lean NAFLD versus healthy subjects. (A) ALT, (B) ALP,
(C) total bilirubin, (D) creatinine, (E) CRP, and (F) uric acid. The graph represents effect size from each study and black square represents
the pooled effect size.
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FIG. 4. Pooled data on metabolic syndrome and its components in subjects with obese versus lean NAFLD. (A) Central obesity,
(B) hypertension, (C) type 2 diabetes mellitus, (D) impaired fasting glucose, (E) low HDL, and (F) metabolic syndrome. The graph
represents effect size from each study and black square represents the pooled effect size.
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Subjects with lean NAFLD compared to healthy
subjects without NAFLD had increased odds for central obesity, hypertension, type 2 diabetes mellitus, low
HDL, and metabolic syndrome (Fig. 5A-E). Subjects
with lean NAFLD also had higher odds for impaired
fasting glucose and insulin resistance from four studies on each analysis (OR, 3.06; 95% CI, 2.82-3.32 and
OR, 3.99; 95% CI, 2.40-6.61, respectively; P < 0.001
for all analyses). Data were homogeneous for central
obesity (I2 = 0; P = 0.48), metabolic syndrome (I2 =
45; P = 0.08), and impaired fasting glucose (I2 = 0;
P = 0.46). Remaining analyses showed heterogeneous
data. There was publication bias for analysis on insulin
resistance (Egger’s P = 0.03), but the other analyses did
not show any publication bias (Supporting Table S7).
Odds for presence of PNPLA3 genetic polymorphisms evaluated in three studies comparing subjects
with lean NAFLD with healthy subjects were 2.69fold (P = 0.005) (Fig. 5F). Data were heterogeneous
(I2 = 79%; P = 0.008) without any publication bias
(Egger’s regression test, P = 0.98).

LIVER HISTOLOGY
Because liver biopsies were not performed on
healthy subjects without NAFLD, analysis was only
done to compare 1,388 subjects with obese NAFLD
versus 563 subjects with lean NAFLD from six
studies. Odds of hepatocyte ballooning and lobular
inflammation on pooled data from four studies were
2.4-fold and 1.9-fold higher, respectively, in subjects
with obese NAFLD versus lean NAFLD (Fig. 6A,B).
However, odds of severe steatosis (≥66% hepatocytes
with steatosis) were similar (OR, 0.85; 95% CI, 0.282.57; P = 0.77). The presence of NASH on liver biopsy
on data pooled from five studies was more than 2-fold
more likely with obese NAFLD (Fig. 6C). Data were
homogeneous for ballooning (I2, 43; P = 0.15), lobular
inflammation (I2, 52; P = 0.08), and NASH (I2, 51; P =
0.08). However, there was significant heterogeneity on
steatosis analysis with I2 (P = 89; P < 0.001). All analyses were devoid of any publication bias (Supporting
Table S8).
The severity of NASH and its components were
assessed comparing two groups on the score of the
respective variable. Obese NAFLD compared to
lean NAFLD had a higher mean score for ballooning (0.29), steatosis grade (0.20), and NAS (0.31)
(Supporting Fig. S5A-C). The severity assessment
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did not show any difference on mean score for lobular inflammation comparing subjects with obese versus lean NAFLD, with a mean difference in score of
0.40 (95% CI, −0.11 to 0.90; P = 0.12). Data were
homogeneous for ballooning (I2, 27; P = 0.25), but
significant heterogeneity was observed for analysis on
lobular inflammation (I2 = 92; P < 0.001) and NASH
(I2, 69; P = 0.04). All analyses were devoid of any publication bias (Supporting Table S8).
Pooled data on liver fibrosis from four studies
showed that 890 subjects with obese NAFLD compared to 397 subjects with lean NAFLD were more
than 2.5-fold more likely to have fibrosis (Fig. 6D).
The data were heterogeneous (I2 = 69; P = 0.03)
without any publication bias (Supporting Table S6).
Severity of fibrosis and its stage reported from two
studies showed that mean fibrosis stage tended to
be higher by 0.17 among 641 subjects with obese
NAFLD compared to 206 subjects with lean NAFLD
(P = 0.06) (Supporting Fig. S5D). The data were
homogeneous (I2 = 16; P = 0.28), and publication bias
could not be assessed because there were only two
studies in this analysis.

OUTCOMES

Two studies(23,24) compared patients with obese
NAFLD versus lean NAFLD for overall survival,
hepatic decompensation, and cause of death, whether
liver related or from a cardiovascular cause. The analyses (Fig. 7) demonstrated that lean had better outcomes, with 28% lower odds of mortality compared to
patients with obese NAFLD. The data were homogeneous (I2 = 0), without publication bias (Egger’s P =
0.46). Although the odds for hepatic decompensation
were no different, the odds of liver-related mortality
in one study was 78% lower among patients with lean
NAFLD versus those with obese NAFLD.(24) The
analysis of cardiovascular causes of death was similar
in pooled data from both studies. Data were homogeneous on all analyses without publication bias, except
for the analysis of liver-related decompensation (Fig. 7).

Discussion

The prevalence of lean NAFLD in this pooled
data and meta-analysis is 11.2% in the general population and 25.2% among individuals with NAFLD,
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FIG. 5. Pooled data on metabolic syndrome components and genetics in subjects with lean NAFLD versus healthy subjects. (A) Central
obesity, (B) hypertension, (C) type 2 diabetes mellitus, (D) low HDL, (E) metabolic syndrome, and (F) PNPLA3. The graph represents
effect size from each study and black square represents the pooled effect size.
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FIG. 6. Pooled data on liver histology comparing obese NAFLD versus lean NAFLD. Odds for (A) hepatocyte ballooning, (B) lobular
inflammation, (C) NASH, and (D) fibrosis stage ≥3. The graph represents effect size from each study and black square represents the
pooled effect size.

with the highest prevalence in Asia. Patients with
lean NAFLD versus healthy adults have an abnormal metabolic and inflammatory profile, with higher
prevalence of metabolic syndrome and risk factors for
NAFLD. Further, the metabolic and inflammatory
profile is less severe and more favorable among lean

compared to obese NAFLD. These findings are associated with less severe liver histology in lean NAFLD,
including NASH with its inflammatory components
and fibrosis stage (Table 2).
The prevalence of lean NAFLD across different studies varies from 5% to 26% in the general population and
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FIG. 7. Pooled data on clinical outcomes comparing lean versus obese NAFLD. The forest plot compares patient survival. The table
shows other outcomes for liver-related mortality, cardiovascular-related mortality, and liver decompensation. The graph represents effect
size from each study and black square represents the pooled effect size. Abbreviations: CV, cardiovascular; NA, not applicable.

TABLE 2. SUMMARY OF FINDINGS OF SYSTEMATIC REVIEW AND META-ANALYSIS
Lean NAFLD Versus Healthy Controls

Obese Versus Lean NAFLD

Demographics

Older with higher BMI; no sex difference

Higher BMI; no difference in age and sex

Comorbidities

Higher odds for metabolic syndrome with all its
components

Higher odds for metabolic syndrome with all its components

PNPLA3 and TM6SF2 polymorphisms

Increased odds for PNPLA3 polymorphisms

No difference

Metabolic markers

Increased measurements on insulin resistance and all
components of metabolic syndrome

Increased measurements on insulin resistance and all
components of metabolic syndrome

Biochemical and hematologic

Higher ALT, AST, ALP, serum bilirubin, and serum
creatinine levels

Higher ALT, serum creatinine, and hemoglobin levels

Inflammatory markers

Higher serum uric acid levels

Higher serum CRP and uric acid levels

Liver histology

Not available

Higher odds for NASH with its components and fibrosis
Higher mean score for steatosis grade, ballooning, and NAS
Higher mean fibrosis stage

Liver stiffness measurement

Not available

from 20% to 50% among individuals with NAFLD.(14)
The reasons for this variation across studies are differences in the study population, the method to detect steatosis, and the cutoff to define lean (Table 1). Disease
modifiers, especially genetic predisposition, may also
explain this variation, as observed in this study with subjects with lean NAFLD having higher odds of PNPLA3
polymorphisms compared to healthy individuals.
The presence of NAFLD among individuals with
normal BMI and absence of other known causes of
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Higher mean liver stiffness measurement

steatosis raises a question as to whether lean NAFLD
is a unique syndrome or falls within the spectrum of
metabolic disease and phenotype of typical NAFLD
in individuals who are overweight or obese. BMI is
not a measure of body fat content or a surrogate of
increased waist circumference and abdominal/visceral
obesity, which actually predisposes an individual to steatosis.(19,20) Individuals with lean NAFLD compared
to healthy individuals were more likely to have central obesity with increased waist circumference, other
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components of metabolic syndrome, insulin resistance,
and higher levels of inflammatory markers. Hence, these
individuals have an unhealthy metabolism with a worse
inflammatory profile compared to healthy individuals.
It is suggested that individuals with lean NAFLD have
a gut-dominant pathology with higher primary and
secondary bile acid levels, with changes in gut microbiota predisposing them to NAFLD and NASH.(21) It
can be speculated that individuals with lean NAFLD
have a body composition that favors development of
visceral obesity, insulin resistance, and NAFLD.(22)
Furthermore, metabolic and inflammatory abnormalities were less severe and more favorable among
patients with lean NAFLD compared to those with
obese NAFLD. Data comparing NAFLD versus
without NAFLD in subjects with obesity is not available, with limited evaluation of the specific effect of
NAFLD. These differences between the profiles of
obese versus lean NAFLD may also suggest that lean
NAFLD is in the spectrum of the typical phenotype
of obese NAFLD. Worse metabolic and inflammatory profiles in obese versus lean NAFLD translated
into more advanced liver disease in individuals with
obesity, with higher liver stiffness measurements
and worse histologic findings of severe steatosis,
NASH along with its components, and fibrosis stage.
Similarly, clinical outcomes were worse in individuals with obese versus individuals with lean NAFLD.
Limited prospective data have not reported a transition of lean NAFLD to the obese phenotype to confirm the hypothesis that lean NAFLD is an earlier
stage in the spectrum of NAFLD.(22,23)
A recent elegant study from Australia comparing lean to obese NAFLD confirmed a more favorable metabolic, inflammatory, and metabolic profile.
However, patients with lean NAFLD had higher
bile acid levels, with increased farnesoid X receptor
activity, as reflected in levels of fibroblast growth factor (FGF). This may explain the phenotype of these
lean patients as bile acids and FGF activity are known
to improve metabolism of glucose and lipids as well
as regulate energy expenditure.(24) Further, the gut
microbiome profile was distinctly different in lean
compared to obese NAFLD.(21) These gut-mediated
adaptation mechanisms distinct in lean NAFLD in
this study suggest that lean NAFLD is a distinct phenotype of metabolically obese with normal weight.
Prospective studies will address long-term patient
outcomes of overall and transplant-free survival. In
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the only available prospective study on 307 subjects
with NAFLD, 72 (23.5%) patients with lean NAFLD
had less advanced histologic findings, and this translated into improved survival and outcomes among
lean versus obese NAFLD over a median followup of 49 months.(23) In this study, negative outcomes developed in 9 patients, with 6 patients dying,
2 patients developing hepatocellular carcinoma, and
1 patient developing liver failure.(23) In contrast,
another study on a larger cohort of biopsy-proven
646 patients with NAFLD, lean NAFLD (19% of the
cohort) had a favorable histologic profile, as seen in
our study. However, over a mean follow-up of approximately 20 years, patients with lean NAFLD compared
to those with obese NAFLD had a 2.7-fold increased
risk of liver-related mortality without increased risk
for overall mortality.(22) Pooling these two studies, lean
versus obese NAFLD had better outcomes in terms
of patient survival and liver-related mortality. More
prospective studies with a large sample and long-term
follow-up are needed to examine long-term outcomes
and also fibrosis progression rate among patients with
lean versus obese NAFLD.
A strength of this study is the large sample size
analyzed with inclusion of multiple studies, and it is
the first systematic review and meta-analysis focusing
on lean NAFLD. However, our study suffers from
limitations, especially heterogeneous data on most
of the analyses (Supporting Tables S2-S6). The heterogeneity is likely due to variations on study population, especially a different cutoff to define leanness
(25 in most studies and 23 in some studies; Table 1),
and the observational nature of studies with some
poor quality studies as assessed using the NewcastleOttawa scale. However, after excluding studies that
included individuals who were overweight, the data
that remained unchanged comparing obese versus
lean NAFLD overcame the limitation of BMI cutoff for defining individuals who are lean. Further, the
data are overrepresented with studies from Asia, limiting generalizability and impact on results. In spite of
these limitations, we feel that the study findings are
relevant for physicians in clinical practice to be diligent in individuals with normal BMI but with other
risk factors, especially central obesity, diabetes, and
metabolic syndrome, and to screen them for the presence of NAFLD. Early identification to address their
metabolic abnormalities with counseling for weight
loss will help in preventing progression to a more
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advanced NAFLD spectrum of NASH and/or fibrosis. It has been shown that weight loss of 7% to 10%,
even in individuals with NAFLD and normal BMI,
helps in the regression of NAFLD, with improvement
of metabolic abnormalities.(24)
In summary, lean NAFLD is a recognized distinct
entity with an abnormal metabolic and inflammatory
profile compared to healthy individuals and a more
favorable metabolic, inflammatory, and histologic
profile compared to obese NAFLD. Although limited data suggest better clinical outcomes and natural
history for lean versus obese NAFLD, larger multicenter prospective studies with long-term follow-up
are needed.
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